Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.26 is 52% above its 5-year average of -0.55, near the high end of its 5-year range (-0.62–-0.26).
50.94% above its 12-month average of -0.53.
Reported quarterly EPS; no daily interpolation. Q3 FY2026 (2026-06-30): -0.03.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.26
EARNINGS PER SHARE (EPS) AVG TTM
-0.53
EARNINGS PER SHARE (EPS) AVG 3Y
-0.57
EARNINGS PER SHARE (EPS) AVG 5Y
-0.55
EARNINGS PER SHARE (EPS) AVG 10Y
-0.51
EARNINGS PER SHARE (EPS) AVG 15Y
-0.64
EARNINGS PER SHARE (EPS) AVG 20Y
-0.65
CURRENT VS TTM AVG
+50.94%
CURRENT VS 3Y AVG
+54.39%
CURRENT VS 5Y AVG
+52.29%
CURRENT VS 10Y AVG
+48.93%
CURRENT VS 15Y AVG
+59.21%
CURRENT VS 20Y AVG
+60.25%
Anavex Life Sciences Corp.
Market Cap
$148.27M
Earnings Per Share (EPS)
-0.26
TTM Avg
-0.53
3Y Avg
-0.57
5Y Avg
-0.55
Market Cap
$148.64M
Earnings Per Share (EPS)
-1.81
TTM Avg
-1.58
3Y Avg
-0.32
5Y Avg
-0.34
Market Cap
$148.73M
Earnings Per Share (EPS)
-12.04
TTM Avg
-8.05
3Y Avg
-55.02
5Y Avg
-123.25
Market Cap
$149.36M
Earnings Per Share (EPS)
-1.13
TTM Avg
-2.24
3Y Avg
-2.81
5Y Avg
-2.43
Market Cap
$146.62M
Earnings Per Share (EPS)
-1.64
TTM Avg
-1.85
3Y Avg
-1.46
5Y Avg
-1.46
Market Cap
$146.28M
Earnings Per Share (EPS)
-0.34
TTM Avg
-0.70
3Y Avg
-0.76
5Y Avg
-0.63
Market Cap
$146.27M
Earnings Per Share (EPS)
2.68
TTM Avg
-1.38
3Y Avg
-6.44
5Y Avg
-7.90
Market Cap
$151.01M
Earnings Per Share (EPS)
-0.26
TTM Avg
-0.32
3Y Avg
-0.33
5Y Avg
-0.37
Market Cap
$143.84M
Earnings Per Share (EPS)
-0.61
TTM Avg
-0.35
3Y Avg
-0.32
5Y Avg
-0.30
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anavex Life Sciences Corp. (AVXL) | $148.27M | -0.26 | -0.53 | -0.57 | -0.55 |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.64M | -1.81 | -1.58 | -0.32 | -0.34 |
| Korsana Biosciences, Inc. (KRSA)vs › | $148.73M | -12.04 | -8.05 | -55.02 | -123.25 |
| ALX Oncology Holdings Inc. (ALXO)vs › | $149.36M | -1.13 | -2.24 | -2.81 | -2.43 |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | -1.64 | -1.85 | -1.46 | -1.46 |
| Codexis, Inc. (CDXS)vs › | $146.28M | -0.34 | -0.70 | -0.76 | -0.63 |
| Fortress Biotech, Inc. (FBIOP)vs › | $146.27M | 2.68 | -1.38 | -6.44 | -7.90 |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.01M | -0.26 | -0.32 | -0.33 | -0.37 |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $143.84M | -0.61 | -0.35 | -0.32 | -0.30 |
| Veraxa Biotech Holding AG (VRXA)vs › | $152.72M | N/A | N/A | N/A | N/A |
Trailing EPS (TTM)
$-0.26
Forward EPS (Est.)
$-0.55
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-09-30 | -0.54 |
| 2024-09-30 | -0.52 |
| 2023-09-30 | -0.60 |
| 2022-09-30 | -0.62 |
| 2021-09-30 | -0.54 |
| 2020-09-30 | -0.45 |
| 2019-09-30 | -0.54 |
| 2018-09-30 | -0.39 |
| 2017-09-30 | -0.33 |
| 2016-09-30 | -0.42 |
| 2015-09-30 | -0.65 |
| 2014-09-30 | -1.16 |
| 2013-09-30 | -0.46 |
| 2012-09-30 | -1.18 |
| 2011-09-30 | -1.16 |
| 2010-09-30 | -1.64 |
| 2009-09-30 | -1.09 |
| 2008-09-30 | -1.09 |
| 2007-09-30 | -0.33 |
| 2006-09-30 | -0.01 |
| 2005-09-30 | -0.02 |
| 2004-09-30 | -0.01 |
